WO2020131801A9 - Composition à libération prolongée comprenant un succinate d'acétate d'hydroxypropyl méthylcellulose - Google Patents

Composition à libération prolongée comprenant un succinate d'acétate d'hydroxypropyl méthylcellulose Download PDF

Info

Publication number
WO2020131801A9
WO2020131801A9 PCT/US2019/066737 US2019066737W WO2020131801A9 WO 2020131801 A9 WO2020131801 A9 WO 2020131801A9 US 2019066737 W US2019066737 W US 2019066737W WO 2020131801 A9 WO2020131801 A9 WO 2020131801A9
Authority
WO
WIPO (PCT)
Prior art keywords
active ingredient
sustained release
hpmcas
composition
dosage form
Prior art date
Application number
PCT/US2019/066737
Other languages
English (en)
Other versions
WO2020131801A1 (fr
Inventor
Oliver O. Petermann
Original Assignee
DDP Specialty Electronic Materials US, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DDP Specialty Electronic Materials US, Inc. filed Critical DDP Specialty Electronic Materials US, Inc.
Publication of WO2020131801A1 publication Critical patent/WO2020131801A1/fr
Publication of WO2020131801A9 publication Critical patent/WO2020131801A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08—Cellulose derivatives
    • C08L1/26—Cellulose ethers
    • C08L1/28—Alkyl ethers
    • C08L1/284—Alkyl ethers with hydroxylated hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08—Cellulose derivatives
    • C08L1/32—Cellulose ether-esters

Definitions

  • the present invention relates to a novel sustained release composition, preferably for oral administration, comprising an active ingredient and a hydroxypropyl methylcellulose acetate succinate.
  • Sustained release dosage forms have found wide application in a variety of technology areas such as in personal care and agricultural applications, water treatment and in particular pharmaceutical applications. Sustained release dosage forms are designed to release a finite quantity of an active ingredient into an aqueous environment over an extended period of time. Sustained release pharmaceutical dosage forms are desirable because they provide a method of delivering a long-lasting dose in a single application without overdosing.
  • Known sustained release pharmaceutical dosage forms contain a drug or a vitamin whose release is controlled by a polymeric matrix which, for instance, may comprise one or more water- soluble cellulose ethers. Water-soluble cellulose ethers hydrate on the surface of a tablet to form a gel layer.
  • a fast formation of the gel layer is important to prevent wetting of the interior and disintegration of the tablet core. Once the gel layer is formed, it controls the penetration of additional water into the tablet. As the outer layer fully hydrates and dissolves, an inner layer must replace it and be sufficiently cohesive and continuous to retard the influx of water and control drug diffusion.
  • HPMC hydroxypropyl methylcellulose
  • US 4,734,285 discloses that the release of an active ingredient can be prolonged by employing a fine particle sized HPMC as an excipient in a solid tablet.
  • HPMC is used in commercial oral pharmaceutical formulations as a component of a polymeric matrix providing sustained release of a drug usually at a concentration of 30% to 60% by weight of the oral dosage form. It is a well-known problem in the pharmaceutical art that some patients, especially children or the elderly, or patients with dysphagia, find it difficult to swallow conventional oral dosage forms such as capsules or tablets.
  • the drug administered in the dosage form is a highly dosed drug which, when the drug is formulated with pharmaceutical excipients in the typical amounts included in commercial dosage forms, either makes each dosage form very large or requires the dose to be divided among two or more dosage forms that have to be swallowed at the same time.
  • HPMCAS methylcellulose acetate succinate
  • one aspect of the present invention is a sustained release composition, preferably for oral administration, which comprises an active ingredient mixed with a hydroxypropyl methylcellulose acetate succinate having a total degree of substitution of acetyl and succinoyl groups, DSAc + DSS, of at least 0.75, wherein the concentration of hydroxypropyl methylcellulose acetate succinate is from 0.1 to 20 % by weight of the active ingredient, and wherein the active ingredient has a solubility in water of at least 1 mg/ml.
  • a sustained release composition preferably for oral administration, which comprises an active ingredient mixed with a hydroxypropyl methylcellulose acetate succinate having a total degree of substitution of acetyl and succinoyl groups, DSAc + DSS, of at least 0.75, wherein the concentration of hydroxypropyl methylcellulose acetate succinate is from 0.1 to 20 % by weight of the active ingredient, and wherein the active ingredient has a solubility in water of at least 1 mg/ml.
  • Another aspect of the present invention is a unit dosage form comprising or produced from a sustained release composition as specified above.
  • Yet another aspect of the present invention is the use of a hydroxypropyl
  • methylcellulose acetate succinate having a total degree of substitution of acetyl and succinoyl groups, DSA c + DSs, of at least 0.75 as an excipient of a polymeric matrix providing sustained release of an active ingredient from a solid oral dosage form.
  • Fig. l is a graph showing the release over time of acetaminophen (APAP) from compositions of the invention comprising different concentrations of hydroxypropyl methylcellulose acetate succinate when HPMC capsules size 00 containing the
  • compositions are immersed in 900 ml of 0.1 N HC1 pH 1.1.
  • a specific hydroxypropyl methylcellulose acetate succinate (HPMCAS) is an essential component of the composition to provide sustained release of the active ingredient on oral administration of the composition even when the HPMCAS is present in a very low amount relative to the active ingredient.
  • HPMCAS hydroxypropyl methylcellulose acetate succinate
  • HPMCAS polymers which are suitable for use in the sustained release composition of this invention are described in US 4,226,981 mentions the use of these HPMCAS polymers for enteric film coating of solid dosage forms.
  • US Patent No. 4,365,060 discloses enterosoluble capsules prepared from, e.g., HPMCAS.
  • WO 2913/164122 discloses the use of HPMCAS polymers for production of enteric capsules providing release of an active ingredient in the small intestine.
  • EP 3006049 describes the use of HPMCAS to prepare a solid dispersion of an active ingredient by hot melt extrusion. However these dosage forms are not suggested to provide sustained release of the active ingredient over a period of several hours in an acidic environment.
  • the HPMCAS has a cellulose backbone having b-1,4 glycosidically bound D- glucopyranose repeating units, designated as anhydroglucose units in the context of this invention. At least a part of the hydroxyl groups of the anhydroglucose units are substituted by a combination of methoxyl and hydroxypropoxyl groups.
  • the degree of the substitution of hydroxyl groups of the anhydroglucose units by hydroxypropoxyl groups is expressed by the molar substitution of hydroxypropoxyl groups, the MS(hydroxypropoxyl).
  • the MS(hydroxypropoxyl) is the average number of moles of hydroxypropoxyl groups per anhydroglucose unit in the esterified cellulose ether. It is to be understood that during the hydroxypropylation reaction the hydroxyl group of a
  • hydroxypropoxyl group bound to the cellulose backbone can be further etherified by a methylation agent, and/or a hydroxypropylation agent.
  • hydroxypropylation etherification reactions with respect to the same carbon atom position of an anhydroglucose unit yields a side chain, wherein multiple hydroxypropoxyl groups are covalently bound to each other by ether bonds, each side chain as a whole forming a hydroxypropoxyl substituent to the cellulose backbone.
  • hydroxypropoxyl groups thus has to be interpreted in the context of the MS(hydroxypropoxyl) as referring to the hydroxypropoxyl groups as the constituting units of hydroxypropoxyl substituents, which either comprise a single hydroxypropoxyl group or a side chain as outlined above, wherein two or more hydroxyalkoxy units are covalently bound to each other by ether bonding.
  • the terminal hydroxyl group of a hydroxypropoxyl substituent is further methylated, or not; both methylated and non-methylated hydroxypropoxyl substituents are included for the determination of MS(hydroxypropoxyl).
  • the HPMCAS utilized in the sustained release composition of this invention generally has a molar substitution of hydroxypropoxyl groups in the range 0.05 to 1.00, preferably 0.08 to 0.70, more preferably 0.15 to 0.60, most preferably 0.15 to 0.40, and particularly 0.20 to 0.40.
  • the average number of hydroxyl groups substituted by methoxyl groups, per anhydroglucose unit, is designated as the degree of substitution of methoxyl groups, DS(methoxyl).
  • DS degree of substitution of methoxyl groups
  • the term“hydroxyl groups substituted by methoxyl groups” is to be construed within the present invention to include not only methylated hydroxyl groups directly bound to the carbon atoms of the cellulose backbone, but also methylated hydroxyl groups of hydroxypropoxyl substituents bound to the cellulose backbone.
  • the HPMCAS utilized in the sustained release composition of this invention generally has a DS(methoxyl) in the range of 1.0 to 2.5, preferably from 1.2 to 2.2, more preferably from 1.6 to 2.05, and most preferably from 1.7 to 2.05.
  • An essential feature of the HPMCAS utilized in the sustained release composition of this invention is its total degree of substitution of acetyl and succinoyl groups, DSA c + DSs.
  • the total degree of substitution of acetyl and succinoyl groups, DSA c + DSs is at least 0.75, preferably at least 0.80.
  • the total degree of substitution of acetyl and succinoyl groups, DSA C + DSs is not more than 1.5, preferably not more than 1.0, more preferably not more than 1.0.
  • a HPMCAS having a DSA C + DSs of from 0.75 to 1.0 and particularly from 0.80 to 0.95 is preferred.
  • the HPMCAS utilized in the sustained release composition of this invention has a degree of substitution of acetyl groups of generally at least 0.1, preferably at least 0.3.
  • the HPMCAS generally has a degree of substitution of acetyl groups of up to 0.9, preferably up to 0.70.
  • the HPMCAS has a degree of substitution of acetyl groups of from 0.1 to 0.9 or from 0.3 to 0.7.
  • the HPMCAS utilized in the sustained release composition of this invention has a degree of substitution of succinoyl groups of generally at least 0.1.
  • the HPMCAS generally has a degree of substitution of succinoyl groups of up to 0.9, preferably up to 0.60, more preferably up to 0.55, and most preferably up to 0.50 or up to 0.45.
  • the HPMCAS has a degree of substitution of succinoyl groups of from 0.15 to 0.45.
  • the content of the acetate and succinate ester groups is determined according to “Hypromellose Acetate Succinate, United States Pharmacopeia and National Formulary, NF 29, pp. 1548-1550”. Reported values are corrected for volatiles (determined as described in section“loss on drying” in the above HPMCAS monograph).
  • the content of the ether groups, i.e., the methoxyl and hydroxypropoxyl groups, in the HPMCAS is determined in the same manner as described for“Hypromellose”, United States Pharmacopeia and National Formulary, USP 35, pp 3467-3469.
  • M(AGU) 162.14 Da
  • M(OH) 17.008 Da
  • M(H) 1.008 Da
  • the weight percent is an average weight percentage based on the total weight of the cellulose repeat unit, including all substituents.
  • the content of the methoxyl group is reported based on the mass of the methoxyl group (i.e., -OCH3).
  • the content of the hydroxypropoxyl group is reported based on the mass of the hydroxypropoxyl group
  • the content of the acetyl groups is reported based on the mass of acetyl (-C(0)-CH3).
  • the content of the succinoyl group is reported based on the mass of succinoyl groups (i.e., - C(O) - CH2 - CH2 - COOH).
  • the HPMCAS utilized in the sustained release composition of this invention generally has a weight average molecular weight M w of up to 500,000 Dalton, preferably up to
  • the HPMCAS has a weight average molecular weight M w of at least 10,000 Dalton, preferably at least 12,000 Dalton, more preferably at least 15,000 Dalton, and most preferably at least 20,000 Dalton, and particularly at least 30,000 Dalton.
  • the HPMCAS utilized in the sustained release composition of this invention generally has a Polydispersity M w /M n , i.e., a ratio of weight average molecular weight M w to number average molecular weight M n , of at least 1.5, typically at least 2.1 and often at least 2.9.
  • the HPMCAS generally has a Polydispersity of up to 4.1, preferably of up to 3.9, and most preferably of up to 3.7.
  • Mw and M n are measured according to Journal of Pharmaceutical and Biomedical Analysis 56 (2011) 743 using a mixture of 40 parts by volume of acetonitrile and 60 parts by volume of aqueous buffer containing 50 mM NaH2P04 and 0.1 M NaNCb as mobile phase. The mobile phase is adjusted to a pH of 8.0. The measurement of M w and M n is described in more details in the Examples.
  • the HPMCAS utilized in the sustained release composition of this invention generally has a viscosity of up to 200 mPa-s, preferably up to 100 mPa-s, more preferably up to 50 mPa-s, measured as a 2.0 wt.-% solution of the HPMCAS in 0.43 wt.-% aqueous NaOH at 20 °C.
  • the viscosity is at least 1.2 mPa s, more typically at least 1.8 mPa s, even more typically at least 2.4 mPa s, and most typically at least 2.8 mPa s, measured as a 2.0 wt.-% solution of the HPMCAS in 0.43 wt.-% aqueous NaOH at 20 °C.
  • the 2.0 % by weight solution of the HPMCAS is prepared as described in“Hypromellose Acetate Succinate, United States Pharmacopeia and National Formulary, NF 29, pp. 1548-1550”, followed by an Ubbelohde viscosity measurement according to DIN 51562-1 : 1999-01 (January 1999).
  • composition of this invention are described in EP 2888293 B1 and in the example below.
  • the sustained release composition of the present invention comprises the HPMCAS described above mixed with an active ingredient.
  • the concentration of the HPMCAS is only from 0.1 to 20 weight percent, preferably from 0.5 to 15 weight percent, more preferably from 1 to 10 weight percent, and most preferably from 4 to 8 weight percent, by weight of the active ingredient.
  • the sustained release composition comprises one or more active ingredients, typically one or more physiologically active ingredients, preferably one or more drugs, one or more diagnostic agents, or one or more physiologically active ingredients which are useful for cosmetic or nutritional purposes, such as vitamins, herbals and mineral supplements.
  • active ingredients typically one or more physiologically active ingredients, preferably one or more drugs, one or more diagnostic agents, or one or more physiologically active ingredients which are useful for cosmetic or nutritional purposes, such as vitamins, herbals and mineral supplements.
  • drug denotes a compound having beneficial prophylactic and/or therapeutic properties when administered to an individual, typically a mammal, especially a human individual.
  • the combined amount of the HPMCAS and the active ingredient(s) is preferably at least 50 weight percent, more preferably at least weight 70 percent, and most preferably at least 90 weight percent, based on the total dry weight of the sustained release composition.
  • the combined amount of the HPMCAS and the active ingredient(s) is up to 100 percent, preferably up to 98 percent or up to 95 percent, based on the total dry weight of the sustained release composition.
  • the sustained release composition may comprise optional adjuvants, such as coloring agents, pigments, opacifiers, flavor and taste improvers, antioxidants, surfactants and any combination thereof. Preferred surfactants are described further below.
  • the total amount of optional adjuvants preferably is not more than 50 weight percent, more preferably not more than 30 weight percent, and most preferably not more than 10 weight percent, based on the total dry weight of the sustained release composition.
  • the HPMCAS described above is useful as an excipient for a sustained release dosage form which means that it has the function to regulate the release of an active ingredient from the dosage form over an extended period of time.
  • sustained release is used herein synonymously with the term“controlled release”. Sustained release is an approach by which active ingredients such as physiologically active compounds are made available at a rate and duration designed to accomplish an intended effect.
  • the HPMCAS is useful for forming all or part of a polymeric matrix in which the active ingredient is embedded.
  • the polymeric matrix may additionally comprise one or more other polymers capable of providing sustained release of the active ingredient from the dosage form.
  • the HPMCAS typically constitutes at least 50%, preferably 60-100%, more preferably 70-100%, even more preferably 80-100%, and most preferably 90-100% by weight of the polymeric matrix.
  • one or more other polymers may be selected from cellulose ethers such as hydroxypropyl methylcellulose, hydroxyethyl methylcellulose, methylcellulose, hydroxypropyl cellulose or carboxymethyl cellulose, or they may be selected from other polysaccharides such as sodium alginate or calcium alginate. It is generally preferred that HPMCAS constitutes 100% by weight of the polymeric matrix.
  • the HPMCAS may be included in sustained release dosage forms intended for oral administration of drugs or other physiologically active ingredients and release thereof into the gastrointestinal tract so as to control the absorption rate of the active ingredient to achieve a desired blood plasma profile.
  • the dosage form is designed to provide a constant or nearly constant level of the active ingredient in plasma with reduced fluctuation via a slow, continuous release of the active ingredient over an extended period of time such as a period of between 4 and 30 hours, preferably between 8 and 24 hours to release all or almost all of the active ingredient from the dosage form.
  • sustained release dosage forms such as tablets and capsules wherein the polymer matrix is formed partially or completely from HPMCAS remains intact over an extended time period such as at least 4 hours, preferably at least 6 hours and under optimized conditions at least 8 hours.
  • HPMCAS is hydrated to form a strong swollen layer on the outer surface of the dosage form upon contact with an aqueous liquid at body temperature.
  • the strong swollen layer minimizes the release of the active ingredient caused by erosion of the dosage form. Since the tablets or capsule contents do not disintegrate (i.e.
  • the release of the active ingredient is controlled by the slow diffusion from the swollen layer that has been formed by hydration of the HPMCAS on the outer surface of the dosage form.
  • a strong swollen layer reduces the penetration of water into the sustained release dosage form, which delays the release of the active ingredient, particularly a water-soluble active ingredient, into an aqueous environment due to a reduced amount of water in the zone of the dosage form into which water diffuses and dissolves the active ingredient.
  • the concentration of the HPMCAS is only from 0.1 to 20 wt.-%, preferably from 0.5 to 15 wt.-%, more preferably from 1 to 10 wt.-%, and most preferably from 4 to 8 wt.-% by weight of the active ingredient.
  • the resulting sustained release unit dosage form that comprises or is produced from the sustained release, such as tablet or capsule, is smaller in size and therefore easier to ingest. It has furthermore been found that a satisfactory release rate may be obtained without adding any other excipients to the dosage form though a surfactant may optionally be added during the manufacturing process as a defoaming agent.
  • the present composition may suitably be prepared by providing a solution of HPMCAS in an organic solvent such as ethanol, methanol, isopropanol or acetone or a mixture thereof with water, optionally adding a surfactant to the solution as a processing aid.
  • HPMCAS is generally dissolved in organic solvent at a concentration of 2.0 - 30 weight percent, preferably 3.0 - 20 weight percent, more preferably 5.0 - 15 weight percent, based on the total weight of the HPMCAS and the solvent.
  • the active ingredient in powder or crystalline form and optionally one or more solid excipients may then be mixed with the HPMCAS solution such that the weight of the HPMCAS is from 0.1 to 20 wt.-%, preferably from 0.5 to 15 wt.-%, more preferably from 1 to 10 wt.-%, and most preferably from 4 to 8 wt.-% by weight of the active ingredient.
  • the sustained release composition of the present invention that comprises or consists of the mixture of active ingredient (and optionally one or more solid excipients) and the
  • HPMCAS solution generally comprises the solvent at a concentration of up to 200 %, preferably up to 150 %, more preferably up to 100 percent, and most preferably up to 70 percent by weight of the active ingredient.
  • the amount of the solvent is generally at least 10 %, preferably at least 20 %, more preferably at least 30%, and most preferably at least 50% by weight of the active ingredient.
  • the surfactant may be selected from conventional defoaming agents selected from the group consisting of anionic surfactants with anionic functional groups such as sulfates, sulfonates, phosphates and carboxylates such as alkyl sulfates, e.g.
  • Suitable plasticizers include, for example, phthalic esters, such as dimethyl-, diethyl-, and diisopropyl-phthalate; citric esters, such as triethyl-, tributyl-, acetyltri ethyl- and acetyltributyl-citrate; phosphoric esters, such as triethyl-, tricresyl, and triphenyl-phosphate; alkyl lactate; glycol esters; glycerol and glycerol esters, such as glycerol triacetate also known as triacetine; sucrose esters; oils and fatty acid esters; butyl stearate; dibutyl sebacate; dibutyl tartrate; diisobutyl adipate, tributyrin; propylene glycol; and mixtures thereof.
  • phthalic esters such as dimethyl-, diethyl-, and diisopropyl-phthalate
  • plasticizers or viscosity modifiers are cellulose ethers, such as carboxy methylcellulose, hydroxypropyl cellulose, ethyl cellulose, methylcellulose, hydroxypropylmethylcellulose (HPMC), e.g.
  • a preferred film forming aid is triethyl citrate (TEC).
  • the amount of the plasticizer or viscosity modifier is generally in the range of 0.1 to 5, preferably 0.2 to 2 % by weight of the active ingredient.
  • the sustained release composition comprising HPMCAS admixed with the active ingredient is in the form of a dry powder.
  • the dry powder may be prepared by drying the mixture of the HPMCAS solution and active ingredient, preferably at a temperature of 40-100°C until the mixture has a moisture content of less than 10% by weight, preferably less than 5% by weight, more preferably less than 3% by weight, in particular less than 2% by weight, such as less than 1% by weight, followed by milling or grinding the mixture to granules of a desired particle size in a manner known in the art.
  • the dry powder will typically contain granules comprising the active ingredient partially or completely encased by HPMCAS which facilitates sustained release of the active ingredient as discussed above.
  • the invention relates to a unit dosage form comprising or produced from the sustained release composition of the present invention.
  • the unit dosage form is preferably in the form of a capsule, tablet, pellet, pre-filled syringe or pouch. It is preferably intended for oral administration.
  • the unit dosage form may, for example, be in the form of a tablet comprising compressed granules of the dried composition.
  • the unit dosage form may be in the form of a tablet or pellet prepared by extruding the semi-solid paste prepared as described above and cutting the extruded mass into pieces of an appropriate size followed by drying.
  • the tablet may optionally comprise one or more other excipients, though preferably the HPMCAS is the only excipient included in the dosage form, except that a surfactant, plasticizer or viscosity modifier may optionally be included as indicated above.
  • the unit dosage form may also be a capsule including the dried composition, preferably in the form of dry granules containing the mixture of HPMCAS and active ingredient.
  • the unit dosage form may also be in the form of a syringe or pouch pre-filled with the wet mixture: this dosage form may more readily be administered to young children.
  • the sustained release composition comprises one or more active ingredients, typically one or more physiologically active ingredients as described further above.
  • the dosage form has been found suitable for providing sustained release of active ingredients which are readily soluble in water at physiological pH.
  • “readily soluble” is intended to mean a solubility in water of at least 1 mg/ml.
  • the dosage form is believed to be particularly suited for administering highly dosed drugs, i.e. drugs administered in unit doses of 500 mg or more, as it is possible to provide a unit dose that includes the requisite amount of the active ingredient in a size that makes it easier to ingest.
  • highly dosed drugs are metformin, metformin hydrochloride, acetaminophen (paracetamol) or acetylsalicylic acid.
  • each unit dosage form may typically include 500-1000 mg of the active ingredient.
  • HPMCAS Hydrophilicity Chromatography
  • ester substitutions with acetyl groups (-CO-CH3) and with succinoyl groups (-CO-CH2-CH2-COOH) are determined according to Hypromellose Acetate Succinate, United States Pharmacopeia and National Formulary, NF 29, pp. 1548-1550”. Reported values for ester substitution are corrected for volatiles (determined as described in section “loss on drying” in the above HPMCAS monograph).
  • Mw and M n were measured according to Journal of Pharmaceutical and Biomedical Analysis 56 (2011) 743 unless stated otherwise.
  • the mobile phase was a mixture of 40 parts by volume of acetonitrile and 60 parts by volume of aqueous buffer containing 50 mM NaH2PC>4 and 0.1 M NaNCh. The mobile phase was adjusted to a pH of 8.0. Solutions of the HPMCAS were filtered into a HPLC vial through a syringe filter of 0.45 pm pore size. The exact details of measuring M w, M n and M z are disclosed in the International Patent
  • HPMCAS used for preparing solid dosage forms containing acetaminophen
  • HPMCAS was used that had a DS(Me) of 1.91, an MS(HP) of 0.25, a DS(Ac) of 0.55, a DS(Suc) of 0.28, a Mw of 151 kDa and a viscosity of 2.9 mPa.s when measured as a 2% by weight solution of the HPMCAS in 0.43% by weight aqueous NaOH.
  • the HPMCAS was prepared as follows: glacial acetic acid, acetic anhydride, a hydroxypropyl
  • methylcellulose HPMC
  • succinic anhydride sodium acetate (water free) were introduced in the amounts listed in Table 1 of EP 2888293 B1 into a reaction vessel under thorough stirring.
  • the HPMC had a methoxyl and hydroxypropoxyl substitution as listed in Table 2 of EP 2888293 B1 and a viscosity of about 3 mPa-s, measured as a 2 % solution in water at 20 °C according to ASTM D2363 - 79 (Reapproved 2006).
  • the HPMC is commercially available from DuPont as Methocel E3 LV Premium cellulose ether.
  • the mixture was heated at 85° C with agitation for 3 or 3.5 hours, as listed in Table 1 of EP 2888293 Bl, to effect esterification x L of water was added to the reactor under stirring to precipitate the HPMC AS.
  • the precipitated product was removed from the reactor and washed with y L of water by applying high shear mixing using an Ultra-Turrax stirrer S50-G45 running at 5200 rpm.
  • the numbers of water x and y are listed in Table 1 of EP 2888293 Bl.
  • the product was isolated by filtration and dried at 50°C. The product was then thoroughly washed by repeatedly slurrying the product in excess water using the Ultra- Turrax stirrer S50-G45 and isolating the product by filtration. The washed product was dried again at 50°C.
  • Example 1 Release of Acetaminophen (APAP) from dried HPMC capsules containing HPMCAS
  • the dried capsules were placed in 900 ml of 0. IN HC1 pH 1.1 at 37°C and drug release was measured in a USP II dissolution apparatus at 37°C, 100 rpm, for 22 hours at a wavelength of 243 nm and a path length of 0.1 mm.
  • the release of APAP from the capsules is shown as - A- in Fig. 1 from which it appears that about 80% of the drug was released after 22 hours.
  • Example 2 Release of Acetaminophen (APAP) from dried HPMC capsules containing HPMCAS
  • the dried capsules were placed in 900 ml of 0. IN HC1 pH 1.1 at 37°C and drug release was measured in a USP II dissolution apparatus at 37°C, 100 rpm, for 22 hours at a wavelength of 243 nm and a path length of 0.1 mm.
  • the release of APAP from the capsules is shown as in Fig. 1 from which it appears that about 63% of the drug was released after 22 hours.
  • Example 3 Release of Acetaminophen (APAP) from dried HPMC capsules containing HPMCAS
  • the dried capsules were placed in 900 ml of 0. IN HC1 pH 1.1 at 37°C and drug release was measured in a USP II dissolution apparatus at 37°C, 100 rpm, for 22 hours at a wavelength of 243 nm and a path length of 0.1 mm.
  • the release of APAP from the capsules is shown as - ⁇ - in Fig. 1 from which it appears that about 88% of the drug was released after 22 hours.
  • Example 4 Release of Acetaminophen (APAP) from dried HPMC capsules containing HPMCAS
  • the dried capsules were placed in 900 ml of 0. IN HC1 pH 1.1 at 37°C and drug release was measured in a USP II dissolution apparatus at 37°C, 100 rpm, for 22 hours at a wavelength of 243 nm and a path length of 0.1 mm.
  • the release of APAP from the capsules is shown as - in Fig. 1 from which it appears that about 68% of the drug was released after 22 hours.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition à libération prolongée comprenant un principe actif mélangé avec un succinate d'acétate d'hydroxypropyl méthylcellulose ayant un degré total de substitution des groupes acétyle et succinoyle, DSAc + DSS, d'au moins 0,75, la concentration de succinate d'acétate d'hydroxypropyl méthylcellulose étant de 0,1 à 20 % en poids de l'ingrédient actif, et l'ingrédient actif ayant une solubilité dans l'eau d'au moins 1 mg/ml. La composition à libération prolongée est utile pour préparer une forme posologique orale dans laquelle un médicament est formulé avec une quantité réduite d'excipients pour permettre une réduction de la taille globale de la forme posologique et améliorer la déglutition sans compromettre ses propriétés de libération prolongée.
PCT/US2019/066737 2018-12-18 2019-12-17 Composition à libération prolongée comprenant un succinate d'acétate d'hydroxypropyl méthylcellulose WO2020131801A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18213438.7 2018-12-18
EP18213438 2018-12-18

Publications (2)

Publication Number Publication Date
WO2020131801A1 WO2020131801A1 (fr) 2020-06-25
WO2020131801A9 true WO2020131801A9 (fr) 2020-08-20

Family

ID=64744642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/066737 WO2020131801A1 (fr) 2018-12-18 2019-12-17 Composition à libération prolongée comprenant un succinate d'acétate d'hydroxypropyl méthylcellulose

Country Status (1)

Country Link
WO (1) WO2020131801A1 (fr)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226981A (en) 1977-09-28 1980-10-07 Shin-Etsu Chemical Co., Ltd. Ether-ester derivatives of cellulose and their applications
US4365060A (en) 1979-04-28 1982-12-21 Shin-Etsu Chemical Co. Ltd. Enterosoluble capsules
US4734285A (en) 1985-10-28 1988-03-29 The Dow Chemical Company Sustained release compositions
WO2005115330A2 (fr) * 2004-05-28 2005-12-08 Pfizer Products Inc. Compositions pharmaceutiques aux performances accrues
KR100858848B1 (ko) * 2006-05-23 2008-09-17 한올제약주식회사 메트포르민 서방정
US10525010B2 (en) 2012-05-02 2020-01-07 Capsugel Belgium Nv Aqueous dispersions of controlled release polymers and shells and capsules thereof
EP2888293B1 (fr) 2012-08-24 2019-05-08 Dow Global Technologies LLC Nouveaux acétate-succinates d'hydroxyalkylméthylcellulose
EP2964678B1 (fr) 2013-03-07 2018-04-04 Dow Global Technologies LLC Nouveaux éthers de cellulose estérifiés de faible viscosité
KR102228157B1 (ko) 2013-06-03 2021-03-17 신에쓰 가가꾸 고교 가부시끼가이샤 가열 용융 압출용 조성물 및 이것을 사용한 가열 용융 압출 성형물의 제조 방법
CN107428847B (zh) * 2015-03-16 2018-11-16 陶氏环球技术有限责任公司 具有低中和度的水溶性酯化纤维素醚

Also Published As

Publication number Publication date
WO2020131801A1 (fr) 2020-06-25

Similar Documents

Publication Publication Date Title
EP3270971B1 (fr) Éthers de cellulose estérifiée solubles dans l'eau ayant un degré de neutralisation faible
KR100660594B1 (ko) 방출 조절형 제제중의 프리젤라틴화 전분
EP2964203B1 (fr) Nouveaux éthers de cellulose estérifiés de très haut poids moléculaire
EP3504246B1 (fr) Acéto-phtalates d'éther de cellulose
EP3475309B1 (fr) Éthers de cellulose estérifiés comprenant des groupes phtalyle
WO2019022819A1 (fr) Procédé pour la production d'hydrogels à base d'éthers de cellulose estérifiés de faible masse moléculaire
WO2020131801A1 (fr) Composition à libération prolongée comprenant un succinate d'acétate d'hydroxypropyl méthylcellulose
WO2020131785A1 (fr) Composition à libération prolongée comprenant un succinate d'acétate d'hydroxypropyl méthylcellulose
WO2018039214A1 (fr) Éthers de cellulose estérifiés comprenant des groupes maléyle
EP3897729B1 (fr) Composition à libération prolongée comprenant une méthylcellulose
JP2022515068A (ja) メチルセルロースを含む徐放性組成物
WO2019108264A1 (fr) Hydrogels à base d'éthers de cellulose estérifiés
EP3463314B1 (fr) Solution aqueuse d'acetate d'ether de cellulose
US20220062305A1 (en) Sustained release composition comprising an ethylcellulose
JP2024088749A (ja) ヒドロキシアルキルメチルセルロースを含む徐放性組成物
WO2020131800A1 (fr) Composition à libération prolongée comprenant une éthylcellulose
WO2020117736A1 (fr) Acétate-succinates d'hydroxypropylméthylcellulose de masse moléculaire très élevée
WO2019022818A1 (fr) Procédé de production d'hydrogels à base d'éthers de cellulose estérifiés
CN116509842A (zh) 药物组合物及其制备方法和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19839035

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19839035

Country of ref document: EP

Kind code of ref document: A1